Sekisui XenoTech Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Sekisui XenoTech's estimated annual revenue is currently $26.3M per year.(i)
  • Sekisui XenoTech's estimated revenue per employee is $201,000

Employee Data

  • Sekisui XenoTech has 131 Employees.(i)
  • Sekisui XenoTech grew their employee count by -13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.4M470%N/AN/A
#2
$26.3M131-13%N/AN/A
#3
$6.2M31-6%N/AN/A
#4
$27.7M138-14%N/AN/A
#5
$5.4M270%N/AN/A
#6
$68.3M340-1%N/AN/A
#7
$22.1M1104%N/AN/A
#8
$12.3M858%$20MN/A
#9
$3.6M18-22%N/AN/A
#10
$5M2532%N/AN/A
Add Company

Sekisui XenoTech is a global Contract Research Organization (CRO) serving clients with unparalleled experience and expertise in evaluating drug candidates, nutraceuticals, cosmetics, food additives and other compounds known as xenobiotics as substrates, inhibitors and inducers of cytochrome P450, UGT and other drug metabolizing enzymes, as well as drug transporters. We offer a variety of in vitro and in vivo safety assessment studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism research. Sekisui XenoTech's product selection includes a wide-range of high quality standard reagents, from subcellular fractions and hepatocytes to recombinant enzymes, substrates and metabolites. The company can also prepare and deliver custom-designed products and services in respnose to client requests. Sekisui XenoTech has extensive experience with the US FDA, EMA and MHLW governing bodies.

keywords:N/A

N/A

Total Funding

131

Number of Employees

$26.3M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sekisui XenoTech News

2022-04-17 - Global Primary Hepatocytes Market 2022 Segmentation ...

PPA Research Group, Inc. Creative Bioarray; BPS Bioscience, Inc. Epithelix Sàrl; ReachBio LLC; AcceGen; Sekisui XenoTech, LLC; Biopredic...

2022-04-06 - The peptide therapeutics contract API manufacturing market is ...

Alastair Hay (Account Manager, Peptides, Almac); Hideki Kubota (Senior Manager, Peptide Business Project Leader, Sekisui Xenotech)...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.5M1315%N/A
#2
$23.8M1328%N/A
#3
$35.9M1331%N/A
#4
$27.5M13418%N/A
#5
$13.6M13655%N/A